Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 2/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.46 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13379555 | 0.88 | ADRB3 (0.49) | CTPS1ADRB3MAP2K4OPRM1DRD2 | |
| SCHEMBL3124999 | 0.88 | MAP2K4 (0.44) | CTPS1ADRB3MAP2K4OPRM1DRD2 | |
| Hydrochloric Acid SCHEMBL3133610 | 0.86 | MAP2K4 (0.43) | CTPS1ADRB3MAP2K4OPRM1DRD2 | |
| SCHEMBL13355599 | 0.85 | ADRB3 (0.47) | CTPS1ADRB3MAP2K4DRD2DRD4 | |
| SCHEMBL2150553 | 0.82 | NPC1 (0.49) | CTPS1ADRB3MAP2K4DRD2DRD4 | |
| SCHEMBL7330204 | 0.81 | TP53 (0.53) | CTPS1ADRB3MAP2K4BRD4LMNA | |
| SCHEMBL8545390 | 0.81 | F2 (0.64) | ADRB3MAP2K4ADRA1A | |
| SCHEMBL3132409 | 0.80 | CA1 (0.48) | CTPS1ADRB3DRD2DRD4DRD3 | |
| SCHEMBL8546481 | 0.79 | F2 (0.65) | ADRB3MAP2K4ADRA1A | |
| SCHEMBL15946017 | 0.76 | OPRM1 (0.45) | MAP2K4OPRM1BRPF1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-05-26 | — | — | US | disclosed |
| US-9193669-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | CTPS1 1843/4885ADRB3 763/4885MAP2K4 4864/4885 |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | CTPS1 1843/4885ADRB3 763/4885MAP2K4 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.